Skip to content

Search

CP Movetime: A wearable sensor and user interface to reduce sedentary behaviours in non-ambulant children and youth with cerebral palsy

CP Movetime aims to establish and test a technology-based application to improve health outcomes by monitoring device measured sedentary behaviours in non-ambulant children and youth with cerebral palsy.

DEFEND CF: Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis.

Determinants of incomplete vaccination and non-vaccination among WA children

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Determinants of prenatal alcohol exposure among Aboriginal women in the Pilbara: Developing a statistically validated model of prenatal alcohol consumption for evidence based intervention development

Investigators: Dave Tucker (PhD candidate), Associate Professor Roz Walker, Dr Martyn Symonds, Dr Nyanda McBride The overarching aim of the proposed

Developing a ‘Food Atlas’ for Western Australia to map, measure and monitor food access

This unique interdisciplinary project, funded by Healthway, aims to develop a Food Atlas tool for mapping, measuring, and monitoring food access across Western Australia.

Developing a human challenge model of GAS infection

NHMRC funding has been awarded for 4 years to Murdoch Childrens Research Institute for this project, with collaboration from Professor Jonathan Carapetis at The Kids.

Developing and characterising juvenile models of aggressive paediatric brain cancers for the evaluation of novel immunotherapies.

While profound treatment responses have been realised using immunotherapy for some cancer types, this is yet to be seen for paediatric brain cancer patients.

Developing new immune based therapies for neuroblastoma

Neuroblastoma is a complex childhood cancer of the nerve cells and the most common solid tumour in children outside of the brain. The average age of diagnosis is 1-2 years and tragically 50% of children with high-risk neuroblastoma lose their battle within five years.